Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
NHS BLMK Clinical Commissioning Group
Capability House
Silsoe, Bedfordshire
MK45 4HR
UK
Contact person: Samuel Naxton
E-mail: samuel.naxton@attain.co.uk
NUTS: UKH24
Internet address(es)
Main address: https://www.blmkccg.nhs.uk/
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Community Lipid Management Service
Reference number: ACE-0490-2021-BLMK
II.1.2) Main CPV code
85100000
II.1.3) Type of contract
Services
II.1.4) Short description
NHS BLMK Clinical Commissioning Group has awarded a contract to Evexia Health Ltd following an 'Open' procurement process to deliver a new Community Lipid Management Service.
The purpose of the Community Lipid Service is to provide a consistent, evidence-based approach to lipid management across BLMK CCG. The Community Lipid Clinic will form part of a new pathway developed with key stakeholders across BLMK, in line with evidenced-based best practice. The service will be funded to provide clinical activity to optimise lipid management in populations at very high risk of CVD (as defined by the commissioner) and provide clinical assessment for familial hypercholesterolemia in people meeting appropriate clinical criteria (as defined by the commissioner), in line with locally developed evidence-based pathways. The Community Lipid Clinic will accept referrals of people meeting the relevant clinical criteria who are registered with a GP practice in Bedfordshire, Luton and Milton Keynes Integrated Care System.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
200 000.00
GBP
II.2) Description
II.2.3) Place of performance
NUTS code:
UKH24
Main site or place of performance:
Bedfordshire, Luton and Milton Keynes
II.2.4) Description of the procurement
NHS BLMK CCG secured Pathway Transformation Funding (PTF) to support the adoption of a new lipid management pathway and the establishment of community lipid services. The Community Lipid service will offer:
• A full assessment of people referred with CVD and/or FH and also uncontrolled hypercholesterolaemia or mixed dyslipidemia, including review of current and previous lipid lowering treatments, adherence with treatment regimes and any reasons for discontinuation.
• Pharmacological management and monitoring of effectiveness and tolerability in line with pathways agreed with the commissioner.
• Requesting of appropriate pathology tests at appropriate intervals through the relevant pathology system.
• Electronic prescription of relevant medications, in sufficient quantity to meet the requirements for uptitration between review contacts.
• Comprehensive documentation of each clinical contact in the shared clinical record on SystmOne.
• Support for self-management and education on the significance of managing cardiovascular risk factors, including cholesterol.
• Appropriate signposting to other services to support optimisation of health and wellbeing, including weight management, smoking cessation, alcohol support and talking therapies.
• Onward referral to specialist lipid services of patients with uncontrolled lipids despite maximum tolerated oral therapy, in line with criteria and pathways agreed with the commissioner.
• Clinical assessment of people with clinical features suggestive of suspected FH (as defined by the commissioner), with onward referral as appropriate to specialist lipid services.
• Clear treatment plans with appropriate patient-driven uptitration of therapy, timing of repeat lipid testing and scheduling of follow-up to allow maximal impact from each clinical contact.
II.2.5) Award criteria
Quality criterion: Quality
/ Weighting: 100%
Price
/ Weighting:
0%
II.2.11) Information about options
Options:
Yes
Description of options:
Contract duration is for 12 months (01st January 2022 to 31st December 2022) with an option to extend for a further 12 months subject to funding, learning and benefits outcomes.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
No
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2021/S 000-018335
Section V: Award of contract
Contract No: M1J4AY Community Lipid Service 2021-22
Title: Community Lipid Service
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
27/10/2021
V.2.2) Information about tenders
Number of tenders received: 2
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Evexia Health Ltd
2a Malzeard Road
Luton
LU3 1BD
UK
NUTS: UKH21
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 200 000.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
Contract Duration:
12 months with an option to extend for a further 12 months subject to funding, learning and benefits outcomes.
Contract Value:
£100,000 per annum
Total contract value for a 24 month period:
£200,000
VI.4) Procedures for review
VI.4.1) Review body
High Court of Justice of England and Wales
Strand
London
WC2A 2LL
UK
VI.5) Date of dispatch of this notice
24/11/2021